Shares surged as Moderna disclosed that an experimental mRNA-based cancer therapy showed early signs of working in patients with an aggressive blood cancer, adding roughly $12 billion in market value in a single session. The move underscores just how desperately investors want proof that the company's mRNA technology works beyond COVID vaccines — and how thin the evidence remains.
Four Responses in 11 Patients Is Promising, Not Proof. Twelve heavily pretreated patients with relapsed or refractory multiple myeloma received the therapy, and among 11 who could be evaluated, four showed confirmed responses — including two "very good partial responses" — even in patients previously treated with competing targeted drugs. That's a 36% response rate in a tiny sample of the sickest patients. No dose-limiting toxicities or serious treatment-related adverse events were observed, and all five cases of cytokine release syndrome were mild (Grade 1). Encouraging, but far too early to price as a commercial product. The trial began enrolling in late 2025 and isn't expected to finish its primary readout until 2030.
The Real Breakthrough Is the Three-in-One Concept. The therapy is designed to instruct the body to produce three distinct cancer-fighting proteins simultaneously, targeting three different markers on myeloma cells.
All three were detectable in patients' blood, with levels rising at higher doses — a first-in-human validation that mRNA can serve as a factory for multiple complex drugs at once. Yet the therapy "is years from challenging Johnson & Johnson, Pfizer and Regeneron," which already sell approved myeloma treatments. The global multiple myeloma treatment market was roughly $20 billion in 2022 and growing.
The Valuation Already Prices In Tomorrow's Pipeline. At $257.98, Moderna's market cap approaches $103 billion — against trailing twelve-month revenue of just $2.2 billion and a net loss of $2.1 billion in the first half of 2026 alone.
The price-to-sales ratio has ballooned from roughly 4.5x a year ago to over 12x by mid-2026 — and today's pop pushes it even higher. Moderna expects to further cut operating expenses to $4.2–$4.6 billion in 2027, targeting cash breakeven in 2028. That means every dollar of upside hinges on pipeline bets like this one paying off years from now.
The December Catalyst Looms. Updated trial data will be presented at the American Society of Hematology meeting on December 12 — a date that could either validate the rally or deflate it. For a stock up 600% from its 52-week low, the margin for disappointment is razor-thin.